Adnexal Diseases  >>  SGN-15  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SGN-15 / Pfizer
NCT00051584: Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer

Terminated
2
60
US
SGN-15 (cBR96-Doxorubicin Immunoconjugate), Gemzar (Gemcitabine)
Seagen Inc.
Ovarian Neoplasms
 
05/03

Download Options